ACTRN12610000162011已完成1 期
A phase I study to determine the safety and tolerability of Dz13 DNAzyme targeting c-Jun in subjects with nodular Basal Cell Carcinoma.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Histologically proven nodular BCC.
- •Measurable disease of 8-16 mm located on trunk or limbs.
- •Presence of dividing cells as identified histologically.
排除标准
- •Women of childbearing potential.
- •Prior or co-existing malignancy.
- •Radiotherapy to >30% bone marrow in previous three months.
- •Known genetic predisposition to skin cancer.
- •Clinically significant non-malignant disease.
- •Current immunosuppression.
- •History of immune-mediated thrombocytopenia or other platelet disease.
- •History of drug abuse.
- •Enrollment in another clinical study using another investigational agent.
研究者
相似试验
已完成
1 期
Phase I study to evaluate the safety and tolerability of single and multiple doses of intranasal pentosan polysulfate (Rhinosul 'Trademark') in healthy subjectsRespiratory - Other respiratory disorders / diseasesInflammatory and Immune System - AllergiesHay feverAllergic RhinitisACTRN12616000676415Paradigm Biopharmaceuticals18
已完成
不适用
A phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-dose subcutaneous and intravenous administration of OMS721 in healthy subjectsautoimmune diseases10003816NL-OMON42466Omeros Corporation24
已完成
1 期
Inhalation of Leukotriene B4 (LTB4) in patients suffering from BronchiectasisBronchiectasisACTRN12614001199606TB4 Sweden AB30
已完成
1 期
Phase I trial to evaluate the safety and tolerability of GDC-0214 in healthy volunteers and patients with mild asthmaAsthmaRespiratory - AsthmaACTRN12617001227381Genentech, Inc.102
已完成
1 期
Phase I trial to evaluate the safety and tolerability of GDC-4379 in healthy volunteers and patients with mild asthmaRespiratory - AsthmaAsthmaACTRN12619000227190Genentech128